.png){kind=icon}
.png){kind=icon}
Return
Inhibition of urease-mediated ammonia production by 2-octynohydroxamic acid in hepatic encephalopathy
.png){kind=icon}
OA
AI
DOI：10.1038/s41467-024-46481-8.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Hepatic encephalopathy is a neuropsychiatric complication of liver disease which is partly associated with elevated ammonemia. Urea hydrolysis by urease-producing bacteria in the colon is often mentioned as one of the main routes of ammonia production in the body, yet research on treatments targeting bacterial ureases in hepatic encephalopathy is limited. Herein we report a hydroxamate-based urease inhibitor, 2-octynohydroxamic acid, exhibiting improved in vitro potency compared to hydroxamic acids that were previously investigated for hepatic encephalopathy. 2-octynohydroxamic acid shows low cytotoxic and mutagenic potential within a micromolar concentration range as well as reduces ammonemia in rodent models of liver disease. Furthermore, 2-octynohydroxamic acid treatment decreases cerebellar glutamine, a product of ammonia metabolism, in male bile duct ligated rats. A prototype colonic formulation enables reduced systemic exposure to 2-octynohydroxamic acid in male dogs. Overall, this work suggests that urease inhibitors delivered to the colon by means of colonic formulations represent a prospective approach for the treatment of hepatic encephalopathy. Hepatic encephalopathy is a severe complication of liver disease with a growing prevalence. Here, the authors present a hydroxamate-based urease inhibitor to target the production of intestinal ammonia, one of the contributors to the pathogenesis of hepatic encephalopathy.
Keywords:
HYDROXAMIC ACIDS
ANTIBACTERIAL ACTIVITY
DRUG ABSORPTION
MUTAGENICITY
RIFAXIMIN
BRAIN
ACETOHYDROXAMATE
RAT
HYPERAMMONEMIA
PERMEABILITY
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
15.7
Papers:
9.2W
Citations:
91.2W
Organization
View more organizations